

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



国药集团  
SINOPHARM

# 國藥控股股份有限公司 SINOPHARM GROUP CO. LTD.\*

*(A joint stock limited company incorporated in the People's Republic of China with limited liability and carrying on business in Hong Kong as 國控股份有限公司)*  
**(Stock Code: 01099)**

## UPDATE ANNOUNCEMENT ON CONNECTED TRANSACTION RELATING TO FORMATION OF A JOINT VENTURE COMPANY

Reference is made to the announcement (the “**Announcement**”) of Sinopharm Group Co. Ltd. (the “**Company**”) dated 6 July 2020 in relation to the connected transaction relating to the formation of the Joint Venture Company. The Company hereby announces that the Joint Venture Company, namely Sinopharm Smart Technology (Shanghai) Co., Ltd.\*\* (國藥智能科技(上海)有限公司) was established on 6 July 2020. Unless otherwise defined, capitalized terms used herein have the same meanings as defined in the Announcement.

Given that the Joint Venture Company will invest in the establishment of the internet platform company under the national medical and pharmaceutical emergency protection system, and the platform company will be responsible for improving the prevention and control system and mechanism of major epidemics, as well as strengthening the national public health emergency management system, the Company would like to strengthen control over the Joint Venture Company. As approved by the Board of the Company, on 14 October 2020, the Company entered into a supplemental agreement (the “**Supplemental Agreement**”) to the JV Agreement with CNBG, Guangdong Medi-World, Shyndec Pharmaceutical and CSIPI stipulating that the number of the board of directors of the Joint Venture Company is changed from seven to nine, of which the number of directors that the Company is entitled to appoint increases from three to five, while each of CNBG, Guangdong Medi-World, Shyndec Pharmaceutical and CSIPI has the right to appoint one director. The Joint Venture Company will resolve to make amendments to the Articles of Association of the Joint Venture Company at the general meeting of the shareholders to reflect the above amendments to the composition of the board of directors of the Joint Venture Company.

Pursuant to the Supplemental Agreement, the Company has effective control over the composition of the board of directors of the Joint Venture Company, and the Joint Venture Company will become a subsidiary of the Company and its financial results will be consolidated into the Group's financial statements.

Save as disclosed above, other terms of the JV Agreement remains unchanged.

By order of the board  
**Sinopharm Group Co. Ltd.**  
**Li Zhiming**  
*Chairman*

Shanghai, the PRC  
14 October 2020

*As at the date of this announcement, the executive Directors of the Company are Mr. Li Zhiming, Mr. Yu Qingming and Mr. Liu Yong; the non-executive Directors of the Company are Mr. Chen Qiyu, Mr. Ma Ping, Mr. Hu Jianwei, Mr. Deng Jindong, Mr. Wen Deyong, Ms. Guan Xiaohui and Ms. Feng Rongli; and the independent non-executive Directors of the Company are Mr. Zhuo Fumin, Mr. Chen Fangruo, Mr. Li Peiyu, Mr. Wu Tak Lung and Mr. Yu Weifeng.*

*\* The Company is registered as a non-Hong Kong company under the Hong Kong Companies Ordinance under its Chinese name and the English name "Sinopharm Group Co. Ltd."*

*\*\* For identification purpose only*